These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26830481)

  • 1. Hepatic Tumor Metastases Cause Enhanced PEGylated Liposome Uptake by Kupffer Cells.
    Ukawa M; Fujiwara Y; Ando H; Shimizu T; Ishida T
    Biol Pharm Bull; 2016; 39(2):215-20. PubMed ID: 26830481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver metastases from colorectal cancer: drug delivery with liposome-encapsulated doxorubicin.
    Cay O; Kruskal JB; Nasser I; Thomas P; Clouse ME
    Radiology; 1997 Oct; 205(1):95-101. PubMed ID: 9314969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
    Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
    Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
    Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application.
    Nagao A; Abu Lila AS; Ishida T; Kiwada H
    Int J Pharm; 2013 Jan; 441(1-2):395-401. PubMed ID: 23174409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes To Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon.
    Lai C; Li C; Luo X; Liu M; Liu X; Hu L; Kang L; Qiu Q; Deng Y; Song Y
    Mol Pharm; 2018 Jul; 15(7):2548-2558. PubMed ID: 29768009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of differently designed immunoliposome formulations in rats with or without hepatic colon cancer metastases.
    Koning GA; Morselt HW; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
    Pharm Res; 2001 Sep; 18(9):1291-8. PubMed ID: 11683242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.
    Ishida T; Ichihara M; Wang X; Yamamoto K; Kimura J; Majima E; Kiwada H
    J Control Release; 2006 May; 112(1):15-25. PubMed ID: 16515818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
    J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry.
    Ando H; Abu Lila AS; Tanaka M; Doi Y; Terada Y; Yagi N; Shimizu T; Okuhira K; Ishima Y; Ishida T
    Mol Pharm; 2018 Feb; 15(2):403-409. PubMed ID: 29287147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-existence of serum-dependent and serum-independent mechanisms for liposome clearance and involvement of non-Kupffer cells in liposome uptake by mouse liver.
    Hu Q; Liu D
    Biochim Biophys Acta; 1996 Oct; 1284(2):153-61. PubMed ID: 8914579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake of phosphatidylserine-containing liposomes by liver sinusoidal endothelial cells in the serum-free perfused rat liver.
    Rothkopf C; Fahr A; Fricker G; Scherphof GL; Kamps JA
    Biochim Biophys Acta; 2005 Feb; 1668(1):10-6. PubMed ID: 15670726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting hepatic cancer cells with pegylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands.
    Medina SH; Tiruchinapally G; Chevliakov MV; Durmaz YY; Stender RN; Ensminger WD; Shewach DS; Elsayed ME
    Adv Healthc Mater; 2013 Oct; 2(10):1337-50. PubMed ID: 23554387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
    Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
    J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kupffer cells determine intrahepatic traffic of PEGylated liposomal doxorubicin.
    Jiang K; Tian K; Yu Y; Wu E; Yang M; Pan F; Qian J; Zhan C
    Nat Commun; 2024 Jul; 15(1):6136. PubMed ID: 39033145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.
    Phillips NC; Tsao MS
    Cancer Res; 1989 Feb; 49(4):936-9. PubMed ID: 2912563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
    Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
    J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.